The Prognostic Value of the Prognostic Nutritional Index in Patients with Advanced or Metastatic Gastric Cancer Treated with Immunotherapy

• Published in: Nutrients Vol. 15; no. 19; p. 4290
• Main Authors: Pan, Yuting, Ma, Yue, Dai, Guanghai
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.10.2023; MDPI
• Subjects: advanced gastric cancer; Antigens; Apoptosis; Biomarkers; Cancer; Cancer therapies; Care and treatment; Chemotherapy; Development and progression; Drug dosages; Gastric cancer; Health aspects; Immune system; Immunotherapy; Ipilimumab; Lymphocytes; Medical prognosis; Metastasis; Monoclonal antibodies; Mortality; Neutrophils; Oncology; Oncology, Experimental; Patients; Prognosis; prognostic factor; prognostic nutritional index; Stomach cancer; survival outcome; China; Taiwan
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu15194290

In recent years, the therapeutic effect of monoclonal antibodies against programmed cell death protein-1 (PD-1) in patients with locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer has been confirmed in many studies. The exploration and discovery of new biomarker combinations based on tumor characteristics and tumor microenvironment help screen superior patients and realize precise immunotherapy. As an evaluation index of immunonutritional status, the prognostic nutritional index (PNI) is low cost, simple and easy to obtain, and effective in determining the prognosis of tumor patients. We selected 268 consecutive AGC patients who were treated with ICI therapy from December 2014 to May 2021. We measured their pretreatment of the PNI levels and performed univariate and multivariate Cox regression analyses of progression-free survival (PFS) or overall survival (OS) after ICI therapy. The low pretreatment PNI level of AGC patients was significantly correlated with shorter PFS (p < 0.001) and OS (p < 0.001) after ICI treatment. In univariate and multivariate analyses of the associations between PNI and OS or PFS, PNI is an independent prognostic factor for PFS (HR = 1.511; 95%CI 1.154–1.977; p = 0.003) and OS (HR = 1.431; 95%CI 1.049–1.951; p = 0.024), respectively. Notably, decreased PNI during treatment with ICIs was associated with early relapse and death. Pretreatment with PNI might help to identify AGC patients who will obtain a survival benefit from ICI therapy.